Insulin Biosimilars Market
Report ID: SQMIG35B2206
Report ID: SQMIG35B2206
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35B2206 |
Region:
Global |
Published Date: January, 2025
Pages:
219
|Tables:
90
|Figures:
76
Global Insulin Biosimilars Market size was valued at USD 3.08 Billion in 2024 and is poised to grow from USD 3.27 Billion in 2025 to USD 5.29 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026–2033).
Insulin biosimilars are drugs or products that are like insulin but not identical and can never be termed as the exact copy of original protein. Growing incidence of diabetes is the prime aspect that is projected to boost sales of insulin biosimilars over the coming years. Increasing investments in diabetes R&D and growing need for diabetes management around the world are also slated to augment the demand for insulin biosimilars across the forecast period and beyond. New clinical trials being performed for novel insulin biosimilars are also helping market expansion. The patent expiry of original insulin products is also a key trend that is estimated to create new opportunities for insulin biosimilars market players in the future. However, stringent regulatory mandates and improper clinical acceptance of novel insulin biosimilars are estimated to be key restraints for the overall market development in the long run.
Market snapshot - 2026-2033
Global Market Size
USD 2.9 billion
Largest Segment
Diabetes Type 2
Fastest Growth
Diabetes Type 1
Growth Rate
6.2% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Insulin Biosimilars Market is segmented by Type, Indication, Distribution Channel, and region. Based on Type, the market is segmented into Fast-acting Insulin, Intermediate-acting Insulin and Long-acting Insulin. Based on Indication, the market is segmented into Diabetes Type 1 and Diabetes Type 2. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Long-acting insulin is estimated to account for a dominant share of the global insulin biosimilars market in the future. Growing need for effective diabetes management over long period of time without significant expenses is a key factor allowing this segment to account for a dominant market share.
Meanwhile, the demand for fast-acting insulin is predicted to increase at a rapid pace across the forecast period and beyond. High effectiveness and low cost coupled with quick action are characteristics that are making fast-acting insulin popular among diabetic people around the world.
Type 2 diabetes is projected to account for around 80% of the global insulin biosimilars demand outlook across the forecast period. High number of people suffering from type 2 diabetes around the world is what allows this segment to maintain its prominence. High demand for cost effective type 2 diabetes management solutions will also help this segment expand in the future.
Meanwhile, the demand for insulin biosimilars for type 1 diabetes people is slated to increase at a notable pace over the coming years. Rising incidence of type 1 diabetes among people around the world is also creating demand for insulin biosimilars for type 1 diabetes and helping this segment expand at a robust pace.
To get detailed segments analysis, Request a Free Sample Report
North America is slated to hold sway over global insulin biosimilars demand outlook across the forecast period. High prevalence of diabetic demographic in this region is the key factor supporting its dominance. Poor eating habits and adoption of sedentary lifestyles are key factors that have given rise to incidence of diabetes in North American countries. High healthcare spending potential and the presence of key pharmaceutical companies will also bolster the demand for insulin biosimilars in this region with United States accounting for the largest market share and Canada the second largest in North America.
Rapid urbanization in Asian countries has led to increased prevalence of diabetes among people and this is why the Asia Pacific region is slated to be the fastest-expanding regional market in the world. Increasing investments in healthcare infrastructure development, growing awareness regarding diabetes management, and high adoption of insulin biosimilars are key factors promoting market development. Rapid surge in geriatric population is also an aspect that could change the global insulin biosimilars demand outlook in the future. China, India, Japan, and Indonesia are key markets in this region.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Patent Expiry of Originator Insulin Products
High Incidence of Diabetes
Complex Regulatory Mandates
Issues Regarding Clinical Acceptance
Request Free Customization of this report to help us to meet your business objectives.
Insulin biosimilars market players can capitalize on the increasing incidence of diabetes by marketing their products as the right choice for effective diabetes management. Insulin biosimilar companies should also utilize strategies such as collaborations, partnerships, and mergers to fast-track the development of new insulin biosimilars. Companies can also improve their commercialization times by leveraging lucrative regulatory norms.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, growing prevalence of diabetes and increasing need for effective diabetes management around the world are estimated to bolster the demand for insulin biosimilars over the coming years. High investments in diabetes R&D are also slated to boost market development. However, the imposition of stringent regulatory mandates around the world is slated to slow down insulin biosimilars market growth in the future. Asia Pacific is slated to emerge as the fastest growing market on the back of rising incidence of diabetes and expanding geriatric population. The use of biologic and biosimilar therapies for diabetes management and treatment is slated to create new opportunities for market growth in the future.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 3.08 Billion |
| Market size value in 2033 | USD 5.29 Billion |
| Growth Rate | 6.2% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Insulin Biosimilars Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Insulin Biosimilars Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Insulin Biosimilars Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Insulin Biosimilars Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
